Cargando…
Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation
Drug-induced cardiotoxicity not only leads to the attrition of drugs during development, but also contributes to the high morbidity and mortality rates of cardiovascular diseases. Comprehensive testing for proarrhythmic risks of drugs has been applied in preclinical cardiac safety assessment for ove...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319223/ https://www.ncbi.nlm.nih.gov/pubmed/35890211 http://dx.doi.org/10.3390/pharmaceutics14071313 |
_version_ | 1784755497263431680 |
---|---|
author | Tang, Xiaoli Wang, Zengwu Hu, Shengshou Zhou, Bingying |
author_facet | Tang, Xiaoli Wang, Zengwu Hu, Shengshou Zhou, Bingying |
author_sort | Tang, Xiaoli |
collection | PubMed |
description | Drug-induced cardiotoxicity not only leads to the attrition of drugs during development, but also contributes to the high morbidity and mortality rates of cardiovascular diseases. Comprehensive testing for proarrhythmic risks of drugs has been applied in preclinical cardiac safety assessment for over 15 years. However, other mechanisms of cardiac toxicity have not received such attention. Of them, mitochondrial impairment is a common form of cardiotoxicity and is known to account for over half of cardiovascular adverse-event-related black box warnings imposed by the U.S. Food and Drug Administration. Although it has been studied in great depth, mitochondrial toxicity assessment has not yet been incorporated into routine safety tests for cardiotoxicity at the preclinical stage. This review discusses the main characteristics of mitochondria in cardiomyocytes, drug-induced mitochondrial toxicities, and high-throughput screening strategies for cardiomyocytes, as well as their proposed integration into preclinical safety pharmacology. We emphasize the advantages of using adult human primary cardiomyocytes for the evaluation of mitochondrial morphology and function, and the need for a novel cardiac safety testing platform integrating mitochondrial toxicity and proarrhythmic risk assessments in cardiac safety evaluation. |
format | Online Article Text |
id | pubmed-9319223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93192232022-07-27 Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation Tang, Xiaoli Wang, Zengwu Hu, Shengshou Zhou, Bingying Pharmaceutics Review Drug-induced cardiotoxicity not only leads to the attrition of drugs during development, but also contributes to the high morbidity and mortality rates of cardiovascular diseases. Comprehensive testing for proarrhythmic risks of drugs has been applied in preclinical cardiac safety assessment for over 15 years. However, other mechanisms of cardiac toxicity have not received such attention. Of them, mitochondrial impairment is a common form of cardiotoxicity and is known to account for over half of cardiovascular adverse-event-related black box warnings imposed by the U.S. Food and Drug Administration. Although it has been studied in great depth, mitochondrial toxicity assessment has not yet been incorporated into routine safety tests for cardiotoxicity at the preclinical stage. This review discusses the main characteristics of mitochondria in cardiomyocytes, drug-induced mitochondrial toxicities, and high-throughput screening strategies for cardiomyocytes, as well as their proposed integration into preclinical safety pharmacology. We emphasize the advantages of using adult human primary cardiomyocytes for the evaluation of mitochondrial morphology and function, and the need for a novel cardiac safety testing platform integrating mitochondrial toxicity and proarrhythmic risk assessments in cardiac safety evaluation. MDPI 2022-06-21 /pmc/articles/PMC9319223/ /pubmed/35890211 http://dx.doi.org/10.3390/pharmaceutics14071313 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tang, Xiaoli Wang, Zengwu Hu, Shengshou Zhou, Bingying Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title | Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title_full | Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title_fullStr | Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title_full_unstemmed | Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title_short | Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation |
title_sort | assessing drug-induced mitochondrial toxicity in cardiomyocytes: implications for preclinical cardiac safety evaluation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319223/ https://www.ncbi.nlm.nih.gov/pubmed/35890211 http://dx.doi.org/10.3390/pharmaceutics14071313 |
work_keys_str_mv | AT tangxiaoli assessingdruginducedmitochondrialtoxicityincardiomyocytesimplicationsforpreclinicalcardiacsafetyevaluation AT wangzengwu assessingdruginducedmitochondrialtoxicityincardiomyocytesimplicationsforpreclinicalcardiacsafetyevaluation AT hushengshou assessingdruginducedmitochondrialtoxicityincardiomyocytesimplicationsforpreclinicalcardiacsafetyevaluation AT zhoubingying assessingdruginducedmitochondrialtoxicityincardiomyocytesimplicationsforpreclinicalcardiacsafetyevaluation |